

Author Index for Volume 15

- Abrams K, 349
AGIS Investigators, 299
Ambrosioni E, 201
Ashby D, 349
Azen SP, 489
- Bailey KR, 15
Barros F, 379
Battistutta D, 512
Belizan J, 379
Berry DA, 360
Bhopal R, 331
Blackburn GH, 284
Borenstein M, 411
Borghi C, 201
Bradley EJ, 284
Brooks MM, 437
Buist AS, 154
- Caggiula AW, 44
Campion J, 437
CAST Investigators, 437
CHART Steering Committee, 482
Chen S, 277
Chen TT, 124
Chuang-Stein C, 30
Comstock GW, 247
Connor RJ, 81
Cook NR, 173
Cook RJ, 187
Cowan CD, 24
- Davis CE, 11, 294
Day SJ, 328
Dianzumba S, 395
Doyle SR, 100
Durham K, 512
- Errington D, 349
Everett V, 482
- Farnot U, 379
Fisher LD, 450
Fisher S, 244
Fletcher BJ, 59
Fletcher GF, 59
Frost C, 512
- Gaffney P, 512
Galai N, 165
- Gibson D, 482
Gillis BP, 44
Gooley TA, 450
Gordon I, 77
Gorkin L, 437
Grandits GA, 395
Green A, 512
Greenberg RP, 244
Greer AL, 432
- Hart V, 512
Harvey AJ, 482
Henzlova MJ, 284
Hertert S, 154
Hillis A, 523
Hirst L, 512
Howel D, 331
- Jensen BE, 59
Jones FL, 44
Jones MP, 135
- Katz J, 220
Kerwin A, 1
Kirby AJ, 165
Krol WF, 335
- Lang C, 512
Langer A, 379
Latin American Network for Perinatal and Reproductive Research (LANPER), 379
LeClerq SC, 220
Ledingham RB, 437
Lee JY, 59
Leslie D, 512
Liebson PR, 395
- Magnani B, 201
Marks G, 512
Martin PJ, 450
Maurer E, 44
Meehan RM, 44
Meinert CL, 235
Modification of Diet in Renal Disease Study, 44
Moher D, 503
Moser HW, 161
- Muñoz A, 165
- Nambour Prevention Study Group, 512
Nanda NC, 59
- Oberman A, 59
O'Gorman TW, 135
Orrell E, 512
Osborne ML, 154
OSTR Collaborative Group, 503
Overall JE, 100
- Parmer MKB, 482
Parsons P, 512
Pettinger M, 450
Pradhan EK, 220
Prineas RJ, 395
Prorok PC, 81
- Raczynski BJ, 59
Rogers WJ, 284
Rosier BA, 173
Rubins HB, 7
- Sack D, 360
Sather HN, 489
Schron EB, 437
Simon R, 463
Simon RM, 124
SMILE Study Investigators, 201
SOLVD Close-Out Working Group, 284
Soong S-j, 277
Spechler SJ, 335
- Thall PF, 463
- VA Cooperative Study Group on Gastroesophageal Reflux Disease (GERD), 335
Victoria CG, 379
Villar J, 379
Vollmer WM, 154
- Watson R, 77
West KP, Jr, 220

Wheeler RH, 277
Wiklund I, 437
Willan AR, 211
Williams DH, 294
Williams G, 512

Williford WO, 335
Witte CL, 1
Witte MH, 1
Wittes J, 5, 24
Wolff MC, 360

Woolson RF, 135
Xiang AH, 489
Yamamoto ME, 44

Subject Index for Volume 15

ACE INHIBITOR

Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions, 201

ANALYSIS OF COVARIANCE

Estimating Sample Sizes for Repeated Measurement Designs, 100

ANALYSIS OF VARIANCE

Estimating Sample Sizes for Repeated Measurement Designs, 100

ASSIGNMENT METHODS

Reporting of Assignment Methods in Clinical Trials, 294

AUTOCORRELATION

Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

BASAL CELL CARCINOMA

The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: Design and Baseline Characteristics of Participants, 512

BASELINE CORRECTION

Estimating Sample Sizes for Repeated Measurement Designs, 100

BAYESIAN INFERENCE

A Bayesian Approach to Establishing Sample Size and Monitoring Criteria for Phase II Clinical Trials, 463

Simple Bayesian Analysis in Clinical Trials: A Tutorial, 349

BCG VACCINE

Field Trials of Tuberculosis Vaccines: How Could We Have Done Them Better?, 247

BIOLOGICAL MARKERS

Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

BIVARIATE RESPONSES

Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187

BLOOD PRESSURE MEASUREMENT

Clinically Relevant Measures?, 328
An Optimal Rule for Screening Subjects for Clinical Trials in the Presence of Within-Person Variability, 173

BONE MARROW

TRANSPLANTATION

Simulation as a Design Tool for Phase I/II Clinical Trials: An Example from Bone Marrow Transplantation, 450

BUBBLE SORTING

Extension of One-Sided Test to Multiple Treatment Trials, 124

CANCER CHEMOTHERAPY

A Bayesian Approach to Establishing Sample Size and Monitoring Criteria for Phase II Clinical Trials, 463

CANCER SCREENING

Issues in the Mortality Analysis of Randomized Controlled Trials of Cancer Screening, 81

CARDIAC REHABILITATION

Design of the Training Levels Comparison Trial, 59

CATARACT

The Nambour Skin Cancer and Actinic Eye Disease Prevention Trial: Design and Baseline Characteristics of Participants, 512

CAUSALITY

Suspended Judgment: Assessing Cause and Effect from Trials: A Cautionary Note, 331

CHART

Is Double Data Entry Necessary? The CHART Trials, 482

CHOLESTEROL LOWERING

From Clinical Trials to Clinical Practice:
Generalizing from Participant to
Patient, 7

Generalizing from Clinical Trials, 11

CLINICAL PRACTICE

Introduction: From Clinical Trials to
Clinical Practice[m]Four Papers
from a Plenary Session, 5

CLINICAL TRIAL(S)

Design of the Training Levels Comparison
Trial, 59

Echocardiography in Multicenter Clinical
Trials: Experience from the
Treatment of Mild Hypertension
Study, 395

Features of the Nutrient Database and
Analysis System for the
Modification of Diet in Renal
Disease Study, 44

Field Trials of Tuberculosis Vaccines: How
Could We Have Done Them Better?,
247

Introduction: From Clinical Trials to
Clinical Practice[m]Four Papers
from a Plenary Session, 5

Is Double Data Entry Necessary? The
CHART Trials, 482

An Optimal Rule for Screening Subjects
for Clinical Trials in the Presence of
Within-Person Variability, 173

Recruiting Hard-to-Reach Subjects: Is It
Worth the Effort?, 154

Reporting of Assignment Methods in
Clinical Trials, 294

Simulation as a Design Tool for Phase I/II
Clinical Trials: An Example from
Bone Marrow Transplantation, 450

Survival of Myocardial Infarction Long-
Term Evaluation (SMILE) Study:
Rationale, Design, Organization,
and Outcome Definitions, 201

Suspended Judgment: Reactions to the
Motion Picture 'Lorenzo's Oil,' 161

CLINICAL TRIAL DESIGN

The Advanced Glaucoma Intervention
Study (AGIS): 1. Study Design and
Methods and Baseline
Characteristics of Study Patients,
299

A Bayesian Approach to Establishing
Sample Size and Monitoring
Criteria for Phase II Clinical Trials,
463

The Nambour Skin Cancer and Actinic

Eye Disease Prevention Trial:
Design and Baseline Characteristics
of Participants, 512

Simulation as a Design Tool for Phase I/II
Clinical Trials: An Example from
Bone Marrow Transplantation, 450

Survival of Myocardial Infarction Long-
Term Evaluation (SMILE) Study:
Rationale, Design, Organization,
and Outcome Definitions, 201

CLINICAL TRIAL METHODOLOGY

From Clinical Trials to Clinical Practice:
Generalizing from Participant to
Patient, 7

Generalizing from Clinical Trials, 11
Intercept Studies, Clinical Trials, and
Cluster Experiments: To Whom Can
We Extrapolate?, 24

CLOSE-OUT QUESTIONNAIRE

Patient Perception of a Long-term Clinical
Trial: Experience Using a Close-out
Questionnaire in the Studies of Left
Ventricular Dysfunction (SOLVD)
Trial, 284

COMMUNITY-BASED TRIALS

Data Management for Large Community
Trials in Nepal, 220

COMPLIANCE

Recruiting Hard-to-Reach Subjects: Is It
Worth the Effort?, 154

COMPUTING

Data Management for Large Community
Trials in Nepal, 220

CONFIDENCE INTERVALS

The Case for Confidence Intervals in
Controlled Clinical Trials, 411

Interim Monitoring of Bivariate Responses
Using Repeated Confidence
Intervals, 187

CONFIDENCE LIMITS

The Case for Confidence Intervals in
Controlled Clinical Trials, 411

CONSOLIDATED SAFETY DATA

A New Proposal for Benefit-Less-Risk
Analysis in Clinical Trials, 30

CONTINUOUS MONITORING

A Bayesian Approach to Establishing
Sample Size and Monitoring

- Criteria for Phase II Clinical Trials, 463
- CONTROLLED CLINICAL TRIALS**
The Case for Confidence Intervals in Controlled Clinical Trials, 411
- COST EFFECTIVENESS**
An Optimal Rule for Screening Subjects for Clinical Trials in the Presence of Within-Person Variability, 173
- DATA MANAGEMENT**
Data Management for Large Community Trials in Nepal, 220
- DATA PROCESSING**
Data Management for Large Community Trials in Nepal, 220
- DECISION MAKING**
Decision Making during a Phase III Randomized Controlled Trial, 360
- DIET**
Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44
- DIETARY ANALYSIS**
Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44
- DIFFERENCE SCORES**
Estimating Sample Sizes for Repeated Measurement Designs, 100
- DISCOUNTING PROCEDURE**
A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials, 30
- DISCOVERY IN MEDICINE**
Suspended Judgment: Ignorance and the Process of Learning and Discovery in Medicine, 1
- DOUBLE DATA ENTRY**
Is Double Data Entry Necessary? The CHART Trials, 482
- DOUBLE-MASKED DESIGN**
Suspended Judgement: Seeing Through the Double-Masked Design: A Commentary, 244
- DRUG TRIALS**
Suspended Judgement: Seeing Through the Double-Masked Design: A Commentary, 244
- EARLY STOPPING**
An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277
- ECHOCARDIOGRAPHY**
Echocardiography in Multicenter Clinical Trials: Experience from the Treatment of Mild Hypertension Study, 395
- EDITORIALS**
Farewell Swan Song (editorial), 235
- EFFECT SIZE**
The Case for Confidence Intervals in Controlled Clinical Trials, 411
- EFFICACY**
Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187
- EQUIVALENCE TRIALS**
Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187
- ERRATA, 326**
- EXERCISE**
Design of the Training Levels Comparison Trial, 59
- FACTORIAL DESIGN**
Power Considerations for Testing an Interaction in a $2 \times k$ Factorial Design with a Failure Time Outcome, 489
- FAILURE TIME**
Power Considerations for Testing an Interaction in a $2 \times k$ Factorial Design with a Failure Time Outcome, 489
- GASTROESOPHAGEAL REFLUX DISEASE**
Development for and Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial, 335

GEHAN'S TWO-STAGE PROCEDURE

An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

GENERALIZATION

From Clinical Trials to Clinical Practice: Generalizing from Participant to Patient, 7

Generalizing from Clinical Trials, 11

Generalizing the Results of Randomized Clinical Trials, 15

Intercept Studies, Clinical Trials, and Cluster Experiments: To Whom Can We Extrapolate?, 24

GLAUCOMA

The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

GROUP SEQUENTIAL DESIGN

Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187

HETEROGENEITY

Generalizing the Results of Randomized Clinical Trials, 15

HIV-1

Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

HYPERTENSION

Echocardiography in Multicenter Clinical Trials: Experience from the Treatment of Mild Hypertension Study, 395

HYPOTHESIS TESTING

The Case for Confidence Intervals in Controlled Clinical Trials, 411
Generalizing the Results of Randomized Clinical Trials, 15

INTERACTION

Power Considerations for Testing an Interaction in a $2 \times k$ Factorial Design with a Failure Time Outcome, 489

INTERCEPT STUDIES

Intercept Studies, Clinical Trials, and

Cluster Experiments: To Whom Can We Extrapolate?, 24

LASER SURGERY

The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

LEARNING

Suspended Judgment: Ignorance and the Process of Learning and Discovery in Medicine, 1

LEFT VENTRICULAR DYSFUNCTION (SOLVD)

Patient Perception of a Long-term Clinical Trial: Experience Using a Close-out Questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial, 284

LETTERS TO THE EDITOR, 523

A Note on Sample Size Determination for Comparison of Small Probabilities, 77

LINEAR TREND TESTS

Estimating Sample Sizes for Repeated Measurement Designs, 100

LONG-TERM CLINICAL TRIAL

Patient Perception of a Long-term Clinical Trial: Experience Using a Close-out Questionnaire in the Studies of Left Ventricular Dysfunction (SOLVD) Trial, 284

LONGITUDINAL STUDIES

Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

'LORENZO'S OIL'

Suspended Judgment: Reactions to the Motion Picture 'Lorenzo's Oil,' 161

MANAGEMENT TRIALS

Power Function Arguments in Support of an Alternative Approach for Analyzing Management Trials, 211

MANTEL-HAENSZEL ESTIMATOR

A Comparison of Two Methods of Estimating a Common Risk Difference in a Stratified Analysis of a Multicenter Clinical Trial, 135

MEDICAL PRACTICE

Scientific Knowledge and Social Consensus, 432

METHODOLOGY

Recruiting Hard-to-Reach Subjects: Is It Worth the Effort?, 154

MORICIZINE

Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II), 437

MORTALITY ANALYSIS

Issues in the Mortality Analysis of Randomized Controlled Trials of Cancer Screening, 81

MULTICENTER TRIAL

The Latin American Multicenter Trial on Psychosocial Support During Pregnancy: Methodology and Baseline Comparability, 379

MULTIPLE 2 x 2 TABLES

A Comparison of Two Methods of Estimating a Common Risk Difference in a Stratified Analysis of a Multicenter Clinical Trial, 135

MULTIPLE COMPARISON

Extension of One-Sided Test to Multiple Treatment Trials, 124

MULTIPLE LINEAR REGRESSION

Development for and Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial, 335

MULTIPLE STEP

Extension of One-Sided Test to Multiple Treatment Trials, 124

MYOCARDIAL INFARCTION

Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II), 437

Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions, 201

NEPAL

Data Management for Large Community Trials in Nepal, 220

NEUTRON THERAPY

Simple Bayesian Analysis in Clinical

Trials: A Tutorial, 349

NON-NULL HYPOTHESIS

Power Function Arguments in Support of an Alternative Approach for Analyzing Management Trials, 211

NUTRIENT CALCULATION

Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44

NUTRIENT DATABASE

Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44

ODDS RATIO

Simple Bayesian Analysis in Clinical Trials: A Tutorial, 349

ONE-SIDED TEST

Extension of One-Sided Test to Multiple Treatment Trials, 124

OPEN-ANGLE GLAUCOMA

The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

OUTCOME VARIABLE

Development for and Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial, 335

PLENARY SESSION

Introduction: From Clinical Trials to Clinical Practice[m]Four Papers from a Plenary Session, 5

POWER

Estimating Sample Sizes for Repeated Measurement Designs, 100

Power Considerations for Testing an Interaction in a 2 x k Factorial Design with a Failure Time Outcome, 489

POWER FUNCTION

Power Function Arguments in Support of an Alternative Approach for Analyzing Management Trials, 211

PROBABILITIES

A Note on Sample Size Determination for Comparison of Small Probabilities (letter), 77

PROPORTIONALITY CONSTANT

A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials, 30

PSYCHOTROPIC DRUGS

Suspended Judgement: Seeing Through the Double-Masked Design: A Commentary, 244

QUALITATIVE INTERACTION

Generalizing the Results of Randomized Clinical Trials, 15

QUALITY OF LIFE

Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II), 437

QUERIES

Clinically Relevant Measures?, 328

RANDOMIZATION

Reporting of Assignment Methods in Clinical Trials, 294

RANDOMIZED CLINICAL TRIALS

Generalizing the Results of Randomized Clinical Trials, 15

Is Double Data Entry Necessary? The CHART Trials, 482

Moricizine and Quality of Life in the Cardiac Arrhythmia Suppression Trial II (CAST II), 437

RANDOMIZED CONTROLLED TRIALS

Decision Making during a Phase III Randomized Controlled Trial, 360

Issues in the Mortality Analysis of Randomized Controlled Trials of Cancer Screening, 81

The Latin American Multicenter Trial on Psychosocial Support During Pregnancy: Methodology and Baseline Comparability, 379

The Ottawa Stroke Trials Registry Collaborative Group and the Development of the Ottawa Stroke Trials Registry (OSTR),

RECRUITMENT

Recruiting Hard-to-Reach Subjects: Is It Worth the Effort?, 154

REJECTION ERROR

An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

RENAL DISEASE

Features of the Nutrient Database and Analysis System for the Modification of Diet in Renal Disease Study, 44

REPEATED CONFIDENCE INTERVALS

Interim Monitoring of Bivariate Responses Using Repeated Confidence Intervals, 187

REPEATED MEASUREMENTS

Development for and Results of the Use of a Gastroesophageal Reflux Disease Activity Index as an Outcome Variable in a Clinical Trial, 335
Estimating Sample Sizes for Repeated Measurement Designs, 100

RESPONSE RATE

An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

RISK-ADJUSTED BENEFIT

A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials, 30

SAFETY PROFILE

A New Proposal for Benefit-Less-Risk Analysis in Clinical Trials, 30

SAMPLE SIZE

The Case for Confidence Intervals in Controlled Clinical Trials, 411

Estimating Sample Sizes for Repeated Measurement Designs, 100

Extension of One-Sided Test to Multiple Treatment Trials, 124

A Note on Sample Size Determination for Comparison of Small Probabilities (letter), 77

Power Considerations for Testing an Interaction in a $2 \times k$ Factorial Design with a Failure Time Outcome, 489

Sample Size Estimation Using Repeated Measurements on Biomarkers as Outcomes, 165

SCIENTIFIC KNOWLEDGE

Scientific Knowledge and Social Consensus, 432

SCREENING

An Optimal Rule for Screening Subjects for Clinical Trials in the Presence of Within-Person Variability, 173

SELECTION

Extension of One-Sided Test to Multiple Treatment Trials, 124

SEQUENTIAL DESIGN

An Efficient Multiple-Stage Procedure for Phase II Clinical Trials that Have High Response Rate Objectives, 277

SIGNIFANCE TEST

The Case for Confidence Intervals in Controlled Clinical Trials, 411

SMILE TRIAL

Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions, 201

SOCIAL CONSENSUS

Scientific Knowledge and Social Consensus, 432

SOCIAL SUPPORT

The Latin American Multicenter Trial on Psychosocial Support During Pregnancy: Methodology and Baseline Comparability, 379

STATISTICAL PRECISION

The Case for Confidence Intervals in Controlled Clinical Trials, 411

STATISTICAL SIGNIFICANCE

The Case for Confidence Intervals in Controlled Clinical Trials, 411

STROKE

The Ottawa Stroke Trials Registry Collaborative Group and the Development of the Ottawa Stroke Trials Registry (OSTR),

SUSPENDED JUDGMENT

Assessing Cause and Effect from Trials: A Cautionary Note, 331
Ignorance and the Process of Learning and Discovery in Medicine, 1
Reactions to the Motion Picture 'Lorenzo's Oil,' 161
Seeing Through the Double-Masked Design: A Commentary, 244

SYMMETRY ASSUMPTION

Estimating Sample Sizes for Repeated Measurement Designs, 100

TRABECULECTOMY

The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

TRAINING LEVELS COMPARISON TRIAL

Design of the Training Levels Comparison Trial, 59

TRIAL COMPARISON

Design of the Training Levels Comparison Trial, 59

TRIAL ORGANIZATION

Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study: Rationale, Design, Organization, and Outcome Definitions, 201

TUBERCULOSIS

Field Trials of Tuberculosis Vaccines: How Could We Have Done Them Better?, 247

UNCONTROLLED CLINICAL TRIAL

Suspended Judgment: Reactions to the Motion Picture 'Lorenzo's Oil,' 161

VACCINES

Field Trials of Tuberculosis Vaccines: How Could We Have Done Them Better?, 247

VISUAL ACUITY

The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

VISUAL FIELDS

The Advanced Glaucoma Intervention Study (AGIS): 1. Study Design and Methods and Baseline Characteristics of Study Patients, 299

VITAMIN A

Data Management for Large Community Trials in Nepal, 220

**WEIGHTED LEAST SQUARES
ESTIMATOR**

A Comparison of Two Methods of

Estimating a Common Risk
Difference in a Stratified Analysis of
a Multicenter Clinical Trial, 135

